Streetbeat News

BAYRY

Bayer AG

https://www.bayer.de/

CEO

Werner Baumann

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

5.42

Mkt cap

21B

Volume

499K

High

5.42

P/E Ratio

-15.79

52-wk high

11.33

Low

5.32

Div yield

0.00

52-wk low

5.32

Bayer shareholders urge CEO Bill Anderson to accelerate turnaround efforts to improve efficiency and drug development, aiming to restore confidence and revive the company's share price, which has hit 20-year lows.

Portfolio Pulse from

November 15, 2024 | 6:15 am

Bayer's third-quarter earnings were below expectations due to impairment losses in the Crop Science division. However, the Pharmaceutical business showed strong performance, with sales boosted by Nubeqa and Kerendia.

Portfolio Pulse from

November 12, 2024 | 8:00 pm

Bayer's stock faces risks from litigation and poor M&As, but its low valuation suggests potential long-term upside, especially post-2025. Despite challenges and a dividend cut, Bayer's fundamentals are solid, with a potential 30% annual upside. Consumer Health shows promise, but Crop Science and Pharma face headwinds.

Portfolio Pulse from

November 12, 2024 | 1:45 pm

Bayer's stock is experiencing a significant decline, dropping 11% in German trading, following the company's announcement of a reduced full-year earnings target. The conglomerate also warned of potential lower profits next year due to challenges in the agricultural market.

Portfolio Pulse from

November 12, 2024 | 1:00 pm

Bayer's stock experienced a decline following a profit warning related to its crop-sciences unit, indicating challenges in agricultural demand.

Portfolio Pulse from

November 12, 2024 | 12:30 pm

Bayer has reduced its full-year operating earnings outlook due to weaker agricultural markets in Latin America.

Portfolio Pulse from

November 12, 2024 | 7:00 am

Bayer AG has submitted a marketing authorization application to the European Medicines Agency for its menopause drug elinzanetant, following positive Phase 3 trial results. The drug showed significant reduction in vasomotor symptoms and improved quality of life over 52 weeks.

Portfolio Pulse from Vandana Singh

October 15, 2024 | 1:26 pm

Bayer AG has submitted an application to the European Medicines Agency for the approval of darolutamide, an oral androgen receptor inhibitor, for use in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer. The application is based on positive Phase III ARANOTE trial results.

Portfolio Pulse from Vandana Singh

October 14, 2024 | 3:34 pm

Bayer AG announced positive results from the Phase 3 ARANOTE trial for its prostate cancer drug, darolutamide, showing a significant reduction in the risk of radiological progression or death. Bayer plans to seek expanded use approval globally. The drug, marketed as Nubeqa, has shown consistent benefits across various patient subgroups and has low incidences of adverse events.

Portfolio Pulse from Vandana Singh

September 16, 2024 | 3:11 pm

Roivant Sciences Ltd. has launched a new subsidiary, Pulmovant, to develop and commercialize the pulmonary hypertension drug mosliciguat, in-licensed from Bayer AG. The drug has shown promising results in reducing pulmonary vascular resistance in trials. Roivant's stock is down 1.88% following the announcement.

Portfolio Pulse from Vandana Singh

September 10, 2024 | 6:21 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.